Matinas Bio nearing start of head-to-head study of MAT9001 and Vascepa

Matinas BioPharma (NYSEMKT:MTNB) is now pre-screening patients for its Phase 2 ENHANCE-IT study that will directly compare MAT9001 against Amarin’s (NASDAQ:AMRN) Vascepa (icosapent ethyl) in patients with elevated triglycerides (150 – 499 mg/dL). Enrollment should start in Q1 2020 with topline results expected in H2 2020.

The company says MAT9001, a next-generation omega-3 fatty acid compound, is more effective than Vascepa in lowering high triglycerides.

https://seekingalpha.com/news/3501677-matinas-bio-nearing-start-head-head-study-mat9001-vascepa